European Journal of Nuclear Medicine and Molecular Imaging

Papers
(The H4-Index of European Journal of Nuclear Medicine and Molecular Imaging is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
EANM Springer Prizes 2020 awarded at EANM 2021240
Towards molecular imaging-guided intervention theatres in oncology183
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?154
New technologies—the best is yet to come153
Nuclear imaging and therapy in oncology in Poland in 2021–2022139
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”134
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions128
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands124
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme122
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis98
Cinematic rendering of [18F]FDG-PET/MR98
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study89
Seasonal variation in D2/3 dopamine receptor availability in the human brain87
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis87
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study86
A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer85
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)83
Cadherin-17 as a target for the immunoPET of adenocarcinoma79
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis76
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients75
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study73
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study73
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy71
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard70
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?70
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study70
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI68
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli67
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study66
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function66
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?65
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 263
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma63
68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results62
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence62
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer61
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation61
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer60
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial60
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus60
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?58
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma57
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation57
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers56
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study56
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C55
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement55
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group54
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review49
0.24413800239563